THE LATEST WORD

Top Industry News – March 10, 2010

Posted on March 10th, 2010 | by Rxmedyn | No Comments »

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Cellzome Announces Second Major Strategic Drug Discovery Alliance with

Botox (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults

Quantity vs. Quality: Long-Term Use of Bone-Building Osteoporosis Drugs

Read the rest of this entry »

Top Industry News – March 9, 2010

Posted on March 9th, 2010 | by Rxmedyn | No Comments »

Sanofi and Merck Link Up To Form Animal Health Giant

Genmab Shares Sink As Cancer Drug Fails in Phase III Study

The Potential For Using Algae To Produce Human Therapeutic Proteins

Science World Charmed By Snake Venom

Read the rest of this entry »

Top Industry Stories – March 8, 2010

Posted on March 8th, 2010 | by Rxmedyn | No Comments »

Roche Stops RA Drug Development After Deaths

Pfizer Brings Out Big Guns to Woo Ratiopharm

AstraZeneca Shares Fall After Setback for Colon Cancer Drug

Xenoport, Inc., Restructures to Focus on Key Programs; Includes An Overall Reduction of 50% of XenoPort’s Workforce

Read the rest of this entry »

Top Industry News – March 5, 2010

Posted on March 5th, 2010 | by Rxmedyn | No Comments »

BMS Says Five New Drugs Will Soften the Blow of Plavix

Pfizer, Bristol-Myers Say Clot Drug Meets Goals

Common Osteoporosis Drugs Are Associated With a Decrease in Risk of Breast Cancer

Anavex Comments on Failure of Pfizer and Medivation’s Alzheimer’s Investigational Drug Dimebon

Read the rest of this entry »

Top Industry Stories – March 4, 2010

Posted on March 4th, 2010 | by Rxmedyn | No Comments »

Disappointment at Failure of Pfizer/Medivation’s Alzheimer’s Drug

Teva Regains Exclusivity on Merck Meds

Sanofi’s Cabazitaxel Improves Survival in Prostate Cancer Patients

75 Percent Of Drug Companies Formally Manage Investigator-Initiated Trials

Read the rest of this entry »

Top Industry News, March 3, 2010

Posted on March 3rd, 2010 | by Rxmedyn | No Comments »

FDA Urged To Probe Digital Marketing by Drugmakers

FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients

Bristol-Myers Squibb Promotes President to Chief Executive

Could Anti-Inflammatory Drugs Break Link Between Fat, Diseases?

Read the rest of this entry »

Top Industry Stories – March 2, 2010

Posted on March 2nd, 2010 | by Rxmedyn | No Comments »

Merck’s Millipore Bid May Leave Investors Waiting

Synta Pharmaceuticals Gets FDA Nod to Resume Developing Cancer Drug

Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline

FDA Approves Exalgo Extended-Release Tablets

Read the rest of this entry »

Top Industry Stories – March 1, 2010

Posted on March 1st, 2010 | by Rxmedyn | No Comments »

US Acts to Fast-track New Drugs

Merck Announces Robust Integrated Pipeline With More Than 20 Medicines and Vaccines in Late-Stage Development

Top Pharmaceutical and Biotech Companies Face Slow Down in Sales Growth Over 2008–14

GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia

Read the rest of this entry »

Top Industry News – February 26, 2010

Posted on February 26th, 2010 | by Rxmedyn | No Comments »

Regulus and Glaxo Will Work on Hepatitis C Drugs

Lilly Settlement to Fund MT Mental Health Services

KV to Close Ethex Unit and Plead Guilty to Charges

Philippines to Lower Prices on More Medicines

Read the rest of this entry »

Top Industry Stories – February 25, 2010

Posted on February 25th, 2010 | by Rxmedyn | No Comments »

GSK Says Report on Avandia Ignores “Scientifically Sound” Info

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

Pfizer’s Prevnar 13 Recommended by CDC’s Advisory Committee On Immunization Practices

Panel Recommends Annual Flu Vaccinations For All